Molybdenum cluster loaded PLGA nanoparticles: An innovative theranostic approach for the treatment of ovarian cancer.
Eur J Pharm Biopharm
; 125: 95-105, 2018 Apr.
Article
em En
| MEDLINE
| ID: mdl-29355686
We evaluate poly (d,l-lactide-co-glycolide) (PLGA) nanoparticles embedding inorganic molybdenum octahedral cluster for photodynamic therapy of cancer (PDT). Tetrabutyl ammonium salt of Mo6Br14 cluster unit, (TBA)2Mo6Br14, presents promising photosensitization activity in the destruction of targeted cancer cells. Stable cluster loaded nanoparticles (CNPs) were prepared by solvent displacement method showing spherical shapes, zeta potential values around -30â¯mV, polydispersity index lower than 0.2 and sizes around 100â¯nm. FT-IR and DSC analysis revealed the lack of strong chemical interaction between the cluster and the polymer within the nanoparticles. In vitro release study showed that (TBA)2Mo6Br14 was totally dissolved in 20â¯min, while CNPs were able to control the release of encapsulated cluster. In vitro cellular viability studies conducted on A2780 ovarian cancer cell line treated up to 72â¯h with cluster or CNPs did not show any sign of toxicity in concentrations up to 20⯵g/ml. This concentration was selected for photo-activation test on A2780 cells and CNPs were able to generate oxygen singlet resulting in a decrease of the cellular viability up to 50%, respectively compared to non-activated conditions. This work presents (TBA)2Mo6Br14 as a novel photosensitizer for PDT and suggests PLGA nanoparticles as an efficient delivery system intended for tumor targeting.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Ácido Poliglicólico
/
Portadores de Fármacos
/
Ácido Láctico
/
Nanopartículas
/
Nanomedicina Teranóstica
/
Molibdênio
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article